NCT07809139尚未招募1 期
A Phase I, Single-Arm, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies
Nanjing Miracle Biotechnology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD)
研究概览
简要总结
Primary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of anti-CD70 chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies.
Secondary Objectives: To characterize the PK profiles of CHT101; to evaluate the clinical efficacy of CHT101 for CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies.
Indication: CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand and voluntarily provide written informed consent (ICF) prior to any study-related assessments/procedures;
- •Aged between 18 and 70 years (inclusive) at the time of ICF signing;
- •CD70-positive tumor cells detected in bone marrow or peripheral blood by flow cytometry, or positive CD70 immunohistochemistry in tumor tissue;
- •Subjects with relapsed/refractory T-cell malignancies with measurable disease as defined by modified Severity-Weighted Assessment Tool (mSWAT) score or peripheral blood tumor burden, or at least one measurable lesion identified by imaging (PET-CT or CT) according to Lugano criteria (lymph node lesion with any diameter >1.5 cm; extranodal lesion with any diameter >1.0 cm), and meeting the following criteria: relapsed/refractory peripheral T-cell lymphoma (including but not limited to peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma, adult T-cell leukemia/lymphoma) or cutaneous T-cell lymphoma (including but not limited to mycosis fungoides or Sézary syndrome [stage IIB or higher with disease involving two or more regions, or single-region disease with large-cell transformation]), and having received prior systemic therapy: subjects with peripheral T-cell lymphoma shall have received at least one line of therapy; subjects with cutaneous T-cell lymphoma shall have received at least two lines of therapy; for anaplastic large-cell lymphoma (ALCL), subjects must have relapsed following prior brentuximab vedotin therapy, or relapsed after ≥2 prior therapies (if anaplastic lymphoma kinase-positive);
- •Subjects with relapsed/refractory B-cell malignancies with at least one measurable lesion and meeting at least one of the following criteria:
- •Indolent lymphoma (FL, MCL, MZL): relapsed or refractory after at least two prior lines of therapy containing a CD20 antibody;
- •Chronic lymphocytic leukemia (CLL): relapsed or refractory after at least two prior lines of therapy including BTK inhibitor and venetoclax;
- •Aggressive or highly aggressive lymphoma (DLBCL, Burkitt lymphoma, high-grade B-cell lymphoma [double-hit, triple-hit, primary mediastinal DLBCL]): relapsed or refractory after at least two prior lines of therapy containing a CD20 antibody and anthracycline, and the subject is ineligible for autologous stem-cell transplantation (conditions for ineligibility for autologous stem-cell transplantation include absence of disease response after salvage therapy, and failure of stem-cell mobilization precluding transplantation);
- •Acute lymphoblastic leukemia (ALL): relapsed or refractory after at least two prior lines of therapy;
- •Histopathologically confirmed classical Hodgkin lymphoma (cHL), relapsed or refractory (following BV and PD-1 therapy), with at least one measurable lesion per the Lugano 2014 lymphoma response evaluation criteria;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 at the time of ICF signing;
- •Expected survival of at least 12 weeks;
- •Fertile male subjects and female subjects of child-bearing potential must agree to use effective contraception from the time of ICF signing until 2 years after administration of investigational product. Female subjects of child-bearing potential include pre-menopausal women and women within 2 years post-menopause. Serum pregnancy test must be negative for female subjects of child-bearing potential at screening.
排除标准
- •Central nervous system (CNS) metastasis, leptomeningeal disease or metastatic central compression; or prior history of CNS diseases, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, etc.;
- •History of organ transplantation;
- •History of other primary malignancies within 5 years prior to study treatment, except for: a) adequately treated and cured carcinoma in situ of the cervix; b) localized basal-cell carcinoma or squamous-cell carcinoma of the skin;
- •Subjects with positive HBV DNA in peripheral blood at screening; subjects positive for hepatitis C virus (HCV) antibody with detectable peripheral blood HCV RNA; subjects positive for human immunodeficiency virus (HIV) antibody; subjects with both positive treponemal-specific antibody and non-treponemal antibody tests for syphilis;
- •Known allergy to any component of study medications, including but not limited to lymphodepleting agents (cyclophosphamide, fludarabine), contrast media for imaging examinations;
- •Prior anti-CD70 antitumor therapy, including but not limited to anti-CD70 cell therapy (autologous or allogeneic), TCR-T therapy, etc.;
- •Prior receipt of CAR-T therapy or other cell/gene therapy;
- •Presence of acute or moderate-to-severe chronic graft-versus-host disease (GVHD) within 4 weeks prior to ICF signing, or receipt of systemic medicinal treatment for GVHD within 4 weeks prior to first infusion;
- •Receipt of any investigational product or systemic antitumor therapy within 28 days prior to first infusion (or five half-lives of the drug, whichever is more appropriate at the investigator's discretion);
- •Receipt of extensive radiotherapy within 28 days prior to ICF signing, except for local radiotherapy for symptomatic relief of non-target lesions administered within 14 days prior to ICF signing or anticipated during the study period;
- •Major surgical procedure within 28 days prior to ICF signing, or anticipated major surgical procedure during the study period;
- •Any uncontrolled active infection requiring parenteral antibiotic, antiviral or antifungal therapy at the time of ICF signing or within 4 weeks prior to first infusion;
- •History of active pulmonary tuberculosis within 1 year before screening (except for subjects with a history of active pulmonary tuberculosis more than 1 year earlier who are judged by the investigator to have no current evidence of active pulmonary tuberculosis);
- •Concurrent or prior history of interstitial lung disease or interstitial pneumonia;
- •Active or previously-occurred autoimmune diseases with potential for relapse (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or at risk for such diseases;
- •Requirement for systemic corticosteroids (≥10 mg/day prednisone equivalent) or other immunosuppressive agents within 2 weeks prior to ICF signing or during the study period, except for: a) intranasal, inhaled, topical steroids or local steroid injection (e.g., intra-articular injection); b) systemic corticosteroids at physiological doses ≤10 mg/day prednisone equivalent; c) steroids for prophylaxis against hypersensitivity reactions (e.g., premedication prior to computed tomography [CT]);
- •Clinically significant thyroid dysfunction as judged by the investigator;
- •Clinically significant cardiovascular disease, including any of the following: a) heart-rate-corrected QT interval (QTcF) >470 msec; b) New York Heart Association (NYHA) class II or higher heart failure; c) left ventricular ejection fraction (LVEF) ≤50%; d) uncontrolled hypertension (systolic blood pressure ≥150 mm Hg and/or diastolic blood pressure ≥95 mm Hg); e) arrhythmias of clinical significance or requiring antiarrhythmic therapy (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes, complete left bundle-branch block, etc.); f) unstable angina or acute myocardial infarction within 6 months prior to ICF signing;
- •Insufficient bone marrow reserve or organ function meeting any of the following laboratory criteria: a) absolute neutrophil count <1.5×10⁹/L; b) platelet count <50×10⁹/L; c) hemoglobin <70 g/L; d) abnormal coagulation parameters: international normalized ratio (INR) >2.0 or prothrombin time (PT) >1.5 × upper limit of normal (ULN); e) alanine aminotransferase (ALT) >2.5 × ULN; f) aspartate aminotransferase (AST) >2.5 × ULN; g) total bilirubin >2.5 × ULN; h) serum creatinine clearance <60 mL/min (calculated by the Cockcroft-Gault formula);
- •History of bleeding events within 6 months prior to ICF signing; clinically significant bleeding requiring medical intervention within 28 days before screening, including esophageal variceal bleeding;
- •Vaccination with live-attenuated/inactivated vaccines within 28 days prior to ICF signing, or planned administration of live-attenuated/inactivated vaccines during the screening period;
- •Subjects whose comorbidities or other circumstances, in the investigator's opinion, may impair protocol compliance or render the subject ineligible for study participation;
- •Female subjects who are pregnant or breastfeeding.
研究组 & 干预措施
Experimental group
Experimental
干预措施: CHT101 (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD)
时间窗: Day 28
To assess the incidence, severity, and relatedness of adverse events (AEs) and serious adverse events (SAEs).
时间窗: Throughout the study period, up to 24 months
次要结局
- PFS(Month 2,Month 3,Month 6,Month 9,Month 12,Month 18,Month 24)
- OS(Month 2,Month 3,Month 6,Month 9,Month 12,Month 18,Month 24)
- Peripheral blood CAR-T cell proportion(Day 1,Day 2,Day 4,Day 7,Day 11,Day 14,Day 18,Day 21,Day 28,Month 2,Month 3,Month 4,Month 5,Month 6,Month 9,Month 12,Month 15,Month 18,Month 21,Month 24)
- ORR(Month 2,Month 3,Month 6,Month 9,Month 12,Month 18,Month 24)
- DOR(Month 2,Month 3,Month 6,Month 9,Month 12,Month 18,Month 24)
- Peripheral blood CAR copy number(Day 1,Day 2,Day 4,Day 7,Day 11,Day 14,Day 18,Day 21,Day 28,Month 2,Month 3,Month 4,Month 5,Month 6,Month 9,Month 12,Month 15,Month 18,Month 21,Month 24)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML2024-514356-33-00Institut De Recherches Internationales Servier IRIS54
招募中
1 期
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type ISpinal Muscular Atrophy 1NCT07554924Lanyue Biotech (Hangzhou) Co., Ltd.11
招募中
1 期
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLESystemic Lupus ErythematosusNCT07318259Chongqing Precision Biotech Co., Ltd18
招募中
1 期
A Clinical Study of Cizutamig in Thyroid Eye DiseaseThyroid Eye Disease, TEDNCT07597200Candid Therapeutics38
撤回
1 期
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid TumorsLymphomaSarcomaNCT07297160Baylor College of Medicine88